Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen.

Venter WDF, Clayden P, Serenata C; OPTIMIZE Consortium.

Curr Opin HIV AIDS. 2017 Jul;12(4):351-354. doi: 10.1097/COH.0000000000000389.

2.

Why a universal antiretroviral regimen?

Flexner CW, Clayden P, Venter WDF.

Curr Opin HIV AIDS. 2017 Jul;12(4):315-317. doi: 10.1097/COH.0000000000000390. No abstract available.

PMID:
28486340
3.

Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.

Slogrove AL, Clayden P, Abrams EJ.

Curr Opin HIV AIDS. 2017 Jul;12(4):359-368. doi: 10.1097/COH.0000000000000386.

PMID:
28426519
4.

When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.

Vitoria M, Ford N, Clayden P, Pozniak AL, Hill AM.

Curr Opin HIV AIDS. 2017 Jul;12(4):414-422. doi: 10.1097/COH.0000000000000380.

5.

Cutting the cost of South African antiretroviral therapy using newer, safer drugs.

Venter WF, Kaiser B, Pillay Y, Conradie F, Gomez GB, Clayden P, Matsolo M, Amole C, Rutter L, Abdullah F, Abrams EJ, Casas CP, Barnhart M, Pillay A, Pozniak A, Hill A, Fairlie L, Boffito M, Moorhouse M, Chersich M, Serenata C, Quevedo J, Loots G.

S Afr Med J. 2016 Dec 21;107(1):28-30. doi: 10.7196/SAMJ.2016.v107.i1.12058.

PMID:
28112085
6.

Paediatric European Network for Treatment of AIDS Treatment Guideline 2016 update: antiretroviral therapy recommended for all children living with HIV.

Foster C, Bamford A, Turkova A, Welch S, Klein N; PENTA Guidelines Writing Group and PENTA steering committee.

HIV Med. 2017 Feb;18(2):133-134. doi: 10.1111/hiv.12399. Epub 2016 Jul 6. No abstract available.

7.

Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption.

Ananworanich J, Melvin D, Amador JT, Childs T, Medin G, Boscolo V, Compagnucci A, Kanjanavanit S, Montero S, Gibb DM; PENTA 11 Study Group.

AIDS. 2016 Apr 24;30(7):1075-81. doi: 10.1097/QAD.0000000000001011.

PMID:
26730569
8.

HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.

Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, McKinney R, Gibb D, Tudor-Williams G; PENPACT-1 (PENTA 9PACTG 390) Study Team.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):42-53. doi: 10.1097/QAI.0000000000000671.

9.

Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals.

Hoehn KB, Gall A, Bashford-Rogers R, Fidler SJ, Kaye S, Weber JN, McClure MO; SPARTAC Trial Investigators, Kellam P, Pybus OG.

Philos Trans R Soc Lond B Biol Sci. 2015 Sep 5;370(1676). pii: 20140241. doi: 10.1098/rstb.2014.0241.

10.

The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels.

Hamlyn E, Stöhr W, Cooper DA, Fisher M, Tambussi G, Schechter M, Miro JM, Vanobberghen F, Babiker A, Weber J, Mcclure M, Porter K, Fidler S; SPARTAC Investigators.

AIDS. 2015 Jul 17;29(11):1355-61. doi: 10.1097/QAD.0000000000000675.

PMID:
25870986
11.

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.

Bamford A, Turkova A, Lyall H, Foster C, Klein N, Bastiaans D, Burger D, Bernadi S, Butler K, Chiappini E, Clayden P, Della Negra M, Giacomet V, Giaquinto C, Gibb D, Galli L, Hainaut M, Koros M, Marques L, Nastouli E, Niehues T, Noguera-Julian A, Rojo P, Rudin C, Scherpbier H, Tudor-Williams G, Welch S; (PENTA Steering Committee).

HIV Med. 2015 Feb 3. doi: 10.1111/hiv.12217. [Epub ahead of print]

12.

Structured observations reveal slow HIV-1 CTL escape.

Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater J; SPARTAC trial investigators.

PLoS Genet. 2015 Feb 2;11(2):e1004914. doi: 10.1371/journal.pgen.1004914. eCollection 2015 Feb.

13.

British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).

de Ruiter A, Taylor GP, Clayden P, Dhar J, Gandhi K, Gilleece Y, Harding K, Hay P, Kennedy J, Low-Beer N, Lyall H, Palfreeman A, O'Shea S, Tookey P, Tosswill J, Welch S, Wilkins E; British HIV Association.

HIV Med. 2014 Sep;15 Suppl 4:1-77. doi: 10.1111/hiv.12185. No abstract available.

14.

Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation.

Yin DE, Warshaw MG, Miller WC, Castro H, Fiscus SA, Harper LM, Harrison LJ, Klein NJ, Lewis J, Melvin AJ, Tudor-Williams G, McKinney RE Jr; PENPACT-1 (PENTA 9/PACTG 390) Study Team.

Pediatrics. 2014 Oct;134(4):e1104-16. doi: 10.1542/peds.2014-0527.

15.

HIV-1 DNA predicts disease progression and post-treatment virological control.

Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J; SPARTACTrial Investigators.

Elife. 2014 Sep 12;3:e03821. doi: 10.7554/eLife.03821.

16.

HIV-1-specific CD4(+) responses in primary HIV-1 infection predict disease progression.

Frater J, Ewings F, Hurst J, Brown H, Robinson N, Fidler S, Babiker A, Weber J, Porter K, Phillips RE; SPARTAC Trial Investigators.

AIDS. 2014 Mar 13;28(5):699-708. doi: 10.1097/QAD.0000000000000130.

PMID:
24549145
17.

Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.

Hamlyn E, Fidler S, Stöhr W, Cooper DA, Tambussi G, Schechter M, Miro JM, Mcclure M, Weber J, Babiker A, Porter K; SPARTAC Trial Investigators.

AIDS. 2014 Mar 27;28(6):869-74. doi: 10.1097/QAD.0000000000000155.

PMID:
24300544
18.

The immunological and virological consequences of planned treatment interruptions in children with HIV infection.

Klein N, Sefe D, Mosconi I, Zanchetta M, Castro H, Jacobsen M, Jones H, Bernardi S, Pillay D, Giaquinto C, Walker AS, Gibb DM, De Rossi A; Paediatric European Network for Treatment of AIDS 11 Trial Team.

PLoS One. 2013 Oct 23;8(10):e76582. doi: 10.1371/journal.pone.0076582. eCollection 2013.

19.

Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters.

Gall A, Kaye S, Hué S, Bonsall D, Rance R, Baillie GJ, Fidler SJ, Weber JN, McClure MO, Kellam P; SPARTAC Trial Investigators.

Retrovirology. 2013 Jan 18;10:8. doi: 10.1186/1742-4690-10-8.

20.

Short-course antiretroviral therapy in primary HIV infection.

SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A.

N Engl J Med. 2013 Jan 17;368(3):207-17. doi: 10.1056/NEJMoa1110039.

Supplemental Content

Loading ...
Support Center